|Day Low/High||40.90 / 42.45|
|52 Wk Low/High||33.50 / 119.92|
Agios owns the full rights to both drugs in the PKD development program, which makes them particularly important to the company.
Announces Innovative $285 Million Follow-on Capital Pool for Special Opportunities
Levi & Korsinsky, LLP announces that it has commenced an investigation of Agios Pharmaceuticals, Inc.
Celgene's days of stellar growth will continue to stretch far into the future.
Celgene Corporation (NASDAQ:CELG) and Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) today announced each company has entered into collaboration agreements with Abbott (NYSE: ABT), a leader in diagnostic technologies, to develop...
The drugmaker plans to submit the first targeted-blood-cancer drug to the U.S. by the end of the year.
Celgene owns the rights to the Agios drug known as AG-221 under an existing partnership.
The most recent short interest data has been released for the 07/29/2016 settlement date, which shows a 680,325 share increase in total short interest for Agios Pharmaceuticals Inc , to 7,219,945, an increase of 10.40% since 07/15/2016. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.
Trade-Ideas LLC identified Agios Pharmaceuticals (AGIO) as a weak on high relative volume candidate